FAST vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

FAST

46.8
AI Score
VS
FAST Wins

MRNA

38.7
AI Score

Investment Advisor Scores

FAST

47score
Recommendation
HOLD

MRNA

39score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric FAST MRNA Winner
Forward P/E 39.2157 23.0415 MRNA
PEG Ratio 3.5417 0 Tie
Revenue Growth 15.5% 29.2% MRNA
Earnings Growth 20.7% -85.1% FAST
Tradestie Score 46.8/100 38.7/100 FAST
Profit Margin 15.6% -110.5% FAST
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY FAST

Relative Price Performance (Last 90 Days)

FAST 1M: +6.8% · 3M: +8.9% MRNA 1M: +2.2% · 3M: +265.4%

Current Technical Phase

FAST

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.5% over 20 days), RSI 71

RSI (14): 70.8 · Price: $55.55

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53

RSI (14): 52.5 · Price: $231.35

Fundamentals Snapshot

Metric FAST MRNA
Market Cap — —
Forward P/E 39.5 -53.3
Trailing P/E 45.1 —
Revenue (TTM) — —
Revenue Growth 0.2% 0.3%
Gross Margin 0.4% -0.4%
Operating Margin 0.2% -0.8%
EPS 1.23 -6.98
Dividend Yield 0.02% —

Frequently Asked Questions

Based on our detailed analysis, FAST is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.